Purify Antigen-specific B Cells From Patients With Rheumatoid Arthritis (CURE RA)

University Hospital Center (CHU)

Status: Unknown

Conditions: Rheumatoid Arthritis

Study type: Observational

Funder types: Other

Identifiers

NCT05203952

RECHMPL21_0735

Details and patient eligibility

About

Rheumatoid arthritis (RA) is an autoimmune disease characterized by the presence of autoantibodies directed against citrullinated proteins, called ACPAs. These antibodies are very specific to RA, and the severity of the disease is closely correlated with the level of these ACPAs, even though they appear much earlier than the clinical signs. Current treatments by biotherapies are effective but only treat the inflammatory symptoms of the disease or, on the contrary, induce a global immunosuppression with a depletion of all B lymphocytes.

Contrary to the current approaches, the CURE RA project proposes a double innovative character:

• The project aims at specifically destroying B lymphocytes expressing / or secreting ACPAs for a more specific approach to RA, without inducing immunosuppression.
• The new therapeutic molecule is entirely original and has no equivalent at present, it uses the target antigens of autoantibodies, the citrullinated peptides, as tools to destroy the pathogenic B cells that express/produce these autoantibodies.

Enrollment: 10 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Antibodies anti-CCP + (ACPA +) > 250 IU/mL

Exclusion criteria

• Current or past Rituximab (Mabthera) treatment past (< 9 months)
• Abatacept treatment